ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,809,593 | +30.5% | 19,325 | +49.5% | 0.01% | +66.7% |
| Q1 2023 | $1,386,247 | -90.3% | 12,929 | -89.0% | 0.00% | -90.6% |
| Q4 2022 | $14,328,658 | +825.0% | 117,323 | +682.2% | 0.03% | +700.0% |
| Q3 2022 | $1,549,000 | +30.4% | 15,000 | +17.3% | 0.00% | +33.3% |
| Q2 2022 | $1,188,000 | -26.1% | 12,785 | -6.7% | 0.00% | 0.0% |
| Q1 2022 | $1,608,000 | -47.8% | 13,705 | -40.1% | 0.00% | -57.1% |
| Q4 2021 | $3,080,000 | -10.1% | 22,895 | +6.6% | 0.01% | -12.5% |
| Q3 2021 | $3,425,000 | +50.8% | 21,487 | +24.4% | 0.01% | +33.3% |
| Q2 2021 | $2,271,000 | +143.1% | 17,267 | +138.2% | 0.01% | +100.0% |
| Q1 2021 | $934,000 | -92.8% | 7,250 | -90.7% | 0.00% | -92.9% |
| Q4 2020 | $12,973,000 | +65.7% | 77,788 | +53.3% | 0.04% | +35.5% |
| Q3 2020 | $7,829,000 | +1075.5% | 50,731 | +1026.9% | 0.03% | +933.3% |
| Q2 2020 | $666,000 | – | 4,502 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |